Inceptionr LLC Takes Position in Acadia Healthcare Company, Inc. (NASDAQ:ACHC)

Inceptionr LLC purchased a new stake in shares of Acadia Healthcare Company, Inc. (NASDAQ:ACHC) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 15,495 shares of the company’s stock, valued at approximately $614,000.

A number of other institutional investors have also recently made changes to their positions in ACHC. Wellington Management Group LLP boosted its holdings in shares of Acadia Healthcare by 12.2% during the 3rd quarter. Wellington Management Group LLP now owns 11,658,253 shares of the company’s stock valued at $739,250,000 after acquiring an additional 1,266,384 shares during the last quarter. Holocene Advisors LP boosted its holdings in shares of Acadia Healthcare by 201.5% during the 3rd quarter. Holocene Advisors LP now owns 972,513 shares of the company’s stock valued at $61,667,000 after acquiring an additional 649,997 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Acadia Healthcare by 17.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,126,607 shares of the company’s stock valued at $198,258,000 after acquiring an additional 454,044 shares during the last quarter. Beach Point Capital Management LP purchased a new stake in shares of Acadia Healthcare during the 4th quarter valued at about $14,097,000. Finally, Bank of Montreal Can boosted its holdings in shares of Acadia Healthcare by 2,456.1% during the 3rd quarter. Bank of Montreal Can now owns 324,569 shares of the company’s stock valued at $20,539,000 after acquiring an additional 311,871 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ACHC shares. TD Cowen lowered their price objective on shares of Acadia Healthcare from $70.00 to $66.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. KeyCorp lowered their price objective on shares of Acadia Healthcare from $70.00 to $65.00 and set an “overweight” rating on the stock in a research note on Monday, March 3rd. Royal Bank of Canada lowered their price objective on shares of Acadia Healthcare from $64.00 to $43.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. Deutsche Bank Aktiengesellschaft upgraded shares of Acadia Healthcare from a “hold” rating to a “buy” rating and increased their price objective for the stock from $45.00 to $75.00 in a research note on Thursday, December 12th. Finally, Barclays cut shares of Acadia Healthcare from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $43.00 to $35.00 in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $56.31.

Acadia Healthcare Price Performance

NASDAQ ACHC opened at $30.57 on Friday. Acadia Healthcare Company, Inc. has a 12 month low of $28.09 and a 12 month high of $84.44. The stock has a market cap of $2.84 billion, a price-to-earnings ratio of 10.02, a PEG ratio of 1.46 and a beta of 1.30. The company’s 50 day moving average is $41.47 and its two-hundred day moving average is $50.72. The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.60.

About Acadia Healthcare

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.